Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29165102 | 0.98 | HPGD (0.31) | ARG1ARG2 | |
| SCHEMBL2372681 | 0.83 | DPP4 (0.37) | — | |
| Hydrochloric Acid SCHEMBL23884910 | 0.81 | DPP4 (0.36) | — | |
| Hydrochloric Acid SCHEMBL3606485 | 0.81 | DPP4 (0.36) | — | |
| SCHEMBL3092435 | 0.81 | TSHR (0.31) | — | |
| SCHEMBL29090720 | 0.80 | IRAK4 (0.37) | — | |
| Hydrochloric Acid SCHEMBL484398 | 0.80 | L3MBTL3 (0.30) | — | |
| Hydrochloric Acid SCHEMBL26131034 | 0.78 | IRAK4 (0.37) | — | |
| SCHEMBL521969 | 0.77 | HRH3 (0.39) | — | |
| Hydrochloric Acid SCHEMBL30879255 | 0.76 | ARG1 (0.33) | ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025077825-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIO-PULMONARY DISORDERS | FAUNA BIO INCORPORATED (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-07-04 | — | — | US | disclosed |
| US-12024499-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-07-02 | — | — | US | disclosed |
| US-12024499-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-07-02 | — | — | US | disclosed |
| US-12024499-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-07-02 | — | — | US | disclosed |
| US-20230002354-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| US-20230002354-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| WO-2022109492-A1 | PYRROLOPYRIDAZINE COMPOUNDS AS KINASE INHIBITORS | GOSSAMER BIOSERVICES, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-11254656-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-02-22 | — | — | US | disclosed |
| US-11254656-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-02-22 | — | — | US | disclosed |
| WO-2010138589-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | GENENTECH, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138589-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | GENENTECH, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| CN-101868464-A | Thienopyrimidiene derivatives as PI3k inhibitors | HOFFMANN LA ROCHE | 2010-10-20 | — | — | CN | disclosed |
| EP-2215090-A1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-08-11 | — | — | EP | disclosed |
| EP-2205610-A1 | THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009053715-A1 | THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009053715-A1 | THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009053716-A1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009053716-A1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| WO-2008152394-A1 | PHARMACEUTICAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002354-A1 | MUSCARINIC AGONISTS | CHRM1, CHRM2, CHRM3 | ARG1 346/4885ARG2 797/4885 |
| US-11254656-B2 | Muscarinic agonists | CHRM1, CHRM2, CHRM3 | ARG1 346/4885ARG2 797/4885 |
| US-12024499-B2 | Muscarinic agonists | CHRM1, CHRM2, CHRM3 | ARG1 346/4885ARG2 797/4885 |
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ADORA2A, ADORA1, ADORA2B | ARG1 3806/4885ARG2 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.